for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cellectar Biosciences Inc

CLRB.OQ

Latest Trade

2.43USD

Change

0.00(0.00%)

Volume

16,666

Today's Range

2.41

 - 

2.48

52 Week Range

1.22

 - 

4.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.43
Open
2.42
Volume
16,666
3M AVG Volume
2.42
Today's High
2.48
Today's Low
2.41
52 Week High
4.25
52 Week Low
1.22
Shares Out (MIL)
9.40
Market Cap (MIL)
22.83
Forward P/E
-1.36
Dividend (Yield %)
--

Next Event

Cellectar Biosciences Inc at Ladenburg Thalmann Healthcare Conference

Latest Developments

More

Cellectar Biosciences Announces Second Quarter 2019 Loss Per Share $0.46

Cellectar Receives FDA Fast Track Designation For Experimental Lymphoma Drug

North Sound Trading LP Reports A 9.0% Passive Stake In Cellectar Biosciences Inc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Industry

Biotechnology & Drugs

Contact Info

100 Campus Dr

+1.608.4418120

http://cellectar.com

Executive Leadership

Stephen Anthony Hill

Chairman of the Board

James V. Caruso

President, Chief Executive Officer, Director

Dov Elefant

Chief Financial Officer

Cameron Szakacs

Vice President - Clinical Development

Jarrod Longcor

Chief Business Officer

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-13.608

2017

-10.706

2018

-5.233

2019(E)

-1.808
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-128.98
Return on Equity (TTM)
-104.48

Latest News

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer

* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER

BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Cellectar Reports 2017 Financial Results

* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma

* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA

BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma

* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions

* CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING

BRIEF-Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131

* CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131

BRIEF-Cellectar Biosciences posts Q3 loss of $0.26 per share

* Cellectar Biosciences reports third quarter 2017 financial and corporate performance

BRIEF-Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma

* Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences announces new preclinical data

* New preclinical data suggest that Cellectar Biosciences' PDC platform provides enhanced outcomes in combination with external radiation

BRIEF-Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan

* Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors

BRIEF-Cellectar Biosciences and Pierre Fabre extend collaboration

* Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates

BRIEF-Cellectar Biosciences reports partial response in a relapsed or refractory multiple myeloma patient treated with CLR 131

* Cellectar Biosciences reports cohort four data and partial response in relapsed or refractory multiple myeloma patient treated with CLR 131

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates

BRIEF-Cellectar Biosciences appoints Jarrod Longcor chief business officer

* Cellectar Biosciences appoints Jarrod Longcor chief business officer Source text for Eikon: Further company coverage:

BRIEF-Cellectar Biosciences reports PDC platform advancement

* Cellectar Biosciences announces significant PDC platform advancement; demonstrates potential to improve therapeutic window Source text for Eikon: Further company coverage: (Reporting by Taenaz Shakir)

BRIEF-Cellectar Biosciences Inc's Chad J. Kolean gave notice to co of his resignation as CFO

* Cellectar Biosciences Inc - Chad J. Kolean gave notice to co of his resignation as vice president, CFO, treasurer of co, effective September 5, 2017

BRIEF-Cellectar Biosciences reports Q2 loss per share $0.23

* Cellectar Biosciences reports second quarter 2017 financial and corporate performance

BRIEF-Cellectar Biosciences signs collaboration with Avicenna Oncology to develop new PDCs for solid tumors

* Cellectar Biosciences signs collaboration with avicenna oncology to develop new PDCs for solid tumors

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up